| Host: |
HEK293 cells |
| Reactivity: |
MERS-CoV |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-MERS-CoV Spike RBD-C-mFc protein was developed from hek293 cells and has a target region of C-mFc. For use in research applications. |
| Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
| Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Human CD26 at 2 Mu g/mL (100 Mu L/well) can bind MERS-CoV Spike RBD with a linear range of 0.5-139.82ng/mL. |
| Immunogen Region: |
Glu367-Tyr606 |
| Immunogen: |
Recombinant MERS-CoV Spike RBD Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Glu367-Tyr606) of mers-cov Spike RBD (Accession #YP_009047204.1) fused with a K9N5Q8. |
| Background | Recombinant MERS-CoV Spike RBD Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Glu367-Tyr606) of mers-cov Spike RBD (Accession #YP_009047204.1) fused with a K9N5Q8. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
